Ann-Hunter Van Kirk

Senior Equity Research Analyst Biopharmaceuticals • Bloomberg Intelligence

Ann-Hunter Van Kirk is a Senior Equity Research Analyst at Bloomberg Intelligence covering the Biopharmaceutical sector with a focus on gene editing, animal health, neuroscience, generics, and eyecare companies. A.H. brings a long career of sell-side healthcare equity research experience from prior positions at Barclays, BMO Capital Markets, and Cantor Fitzgerald. Ms Van Kirk holds a master’s degree from the London School of Economics and two bachelor’s degrees from Southern Methodist University with honours.

Also speaking

Fernanda Masri

Head of Manufacturing Innovation, BD • CGT Catapult

Raja Sharif

Founder & Chief Executive Officer • Hataali

Hans S. Keirstead

Chairman & Chief Executive Officer • AIVITA Biomedical, Inc.

Event Info


Advanced Therapies Investment Summit

Find out more about the Investor Pre-Day taking place 10th September 2024.

2023 Sample Attendee List

Take a look at the sample attendee list for Advanced Therapies Europe 2023 here.